CLONAL EVOLUTION IN MYELODYSPLASIA AND ACUTE MYELOID LEUKAEMIA FOLLOWING AZACITIDINE

Grant number: 1128984 | Funding period: 2017 - 2020

Completed

Abstract

The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) represent a spectrum of clinically heterogeneous malignancies that remain incurable in the vast majority of patients. Whilst the DNA mutations underpinning the initiation/maintenance of these malignancies are largely known we have little insight into how these mutations alter response to therapy. Using a range of sophisticated cutting edge technologies we will study how these DNA mutations evolve over the course of treatment.

Related publications (4)

University of Melbourne Researchers